250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA
Financial Results, Press Release
Investor Presentation
Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Highlights Company Progress and Reports Third Quarter 2025 Financial Results
Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
Septerna Begins Phase 1 Trial of SEP-631 for Mast Cell Diseases
FY 2025
Q3
Q2
Q1
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Certificate
Registration of Securities
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
S-1MEF